STOCK TITAN
  1. Home
  2. Sec-filings
  3. PFE
  4. [Form 4] PFIZER INC Insider Trading Activity

[Form 4] PFIZER INC Insider Trading Activity

Filing Impact
(Very High)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Pfizer Inc. Executive Vice President Michael McDermott reported several equity-related transactions involving Pfizer common stock and stock appreciation rights. On February 25, 2026, he exercised 37,925 stock appreciation rights, which were settled in Pfizer common stock as part of an earn-out of these awards, including dividend equivalents. This exercise generated 37,925 common shares at a reference price of $33.82 per share, increasing his direct common stock holdings.

In connection with this earn-out and related restricted stock unit vesting, Pfizer withheld shares to cover tax obligations and exercise price. These withholding dispositions of common stock totaled 3,503 shares on February 26, 2026 at $27.10, plus 679 shares and 36,044 shares on February 25, 2026 at prices of $27.09 and $26.92 per share, respectively. After these transactions, McDermott directly held 74,308 Pfizer common shares, with the derivative stock appreciation rights position reported as fully settled.

Positive

  • None.

Negative

  • None.
Insider McDermott Michael
Role Executive Vice President
Type Security Shares Price Value
Tax Withholding Common Stock 3,503 $27.10 $95K
Exercise Stock Appreciation Rights 37,925 $0.00 --
Exercise Common Stock 37,925 $33.82 $1.28M
Tax Withholding Common Stock 679 $27.09 $18K
Tax Withholding Common Stock 36,044 $26.92 $970K
Holdings After Transaction: Common Stock — 74,308 shares (Direct); Stock Appreciation Rights — 0 shares (Direct)
Footnotes (1)
  1. The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon). The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights. The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon). Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used. The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the vesting of restricted stock units (including dividend equivalents thereon). The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
McDermott Michael
(Last) (First) (Middle)
66 HUDSON BOULEVARD EAST
ATTN: CORPORATE SECRETARY
(Street)
NEW YORK NY 10001-2192
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
PFIZER INC [ PFE ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Executive Vice President
3. Date of Earliest Transaction (Month/Day/Year)
02/25/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 02/25/2026 M 37,925(1) A $33.82 114,534 D
Common Stock 02/25/2026 F 679(2) D $27.09 113,855 D
Common Stock 02/25/2026 F 36,044(3) D $26.92(4) 77,811 D
Common Stock 02/26/2026 F 3,503(5) D $27.1 74,308 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Appreciation Rights $33.82 02/25/2026 M 37,925 02/25/2026(6) 02/25/2026(6) Common Stock 37,925 $0.0000 0.0000 D
Explanation of Responses:
1. The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon).
2. The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights.
3. The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon).
4. Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used.
5. The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the vesting of restricted stock units (including dividend equivalents thereon).
6. The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant.
/s/ Shanice A. Reid, by power of atty, for Michael McDermott 02/27/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR